Slides

Numerous potential new forms of treatment are being examined in placebo controlled RCTs, case series, and case reports. There is low strength evidence that adding probiotics containing Saccharomyces cerevisiae or Saccharomyces boulardii to antibiotics for primary treatment may increase the risk for fungemia-related complications in critically ill patients and adds no known benefit. Probiotics, prebiotics, and toxin-neutralizing antibodies alone do not reduce primary hospital CDI incidence rates. C. difficile immune whey (CDIW) is well-tolerated and the overall response rate was similar to metronidazole. Fecal flora reconstitution via fecal transplantation prevents recurrent infections for up to 1 year. CDI recurrence rates were reduced three-fold when an oligofructose prebiotic or toxin-neutralizing antibodies were added to standard antibiotics.